Prevalence and clinical characteristics of thyroid disease induced by chronic hepatitis B treated with polyethylene glycol (peg) interferon-α
10.3760/cma.j.issn.1003-9279.2012.02.013
- VernacularTitle:聚乙二醇干扰素α治疗慢性乙型肝炎诱发甲状腺疾病的临床研究
- Author:
Xue-Fu CHEN
1
;
Xiao-Ping CHEN
;
Xiao-Jun MA
;
Wen-Li CHEN
;
Jing HUANG
;
Xiao-Dan LUO
Author Information
1. 广东省医学科学院广东省人民医院
- Keywords:
Polyethylene glycols;
Interferon-alpha;
Hepatitis B,chronic;
Thyroid disease
- From:
Chinese Journal of Experimental and Clinical Virology
2012;26(2):117-119
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the prevalence and clinical characteristics of thyroid disease induced by chronic hepatitis B treated with polyethylene glycol (peg) interferon-α.Methods Totally 210 patients with chronic hepatitis B were monitored for thyroid function and thyroid antibodies before application of polyethylene glycol (peg) interferon-α therapy and every 3 months during and after the treatment.Results After treatment with polyethylene glycol (peg) interferon-α,6.7％ (14/210) of patients had thyroid disease,in which 5.2％ (11/210) had hyperthyroidism and 1.4％ (3/210) had hypothyroidism.The proportion of the hyperthyroidism and hypothyroidism in women were 11.8 ％ ( 6/51 ) and 3.9％ ( 2/51 ),higher than 3.1％ (5/159) and 0.6％ (1/159) in male (P ＜ 0.05).In women subjects,higher proportion of those who developed thyroid disease were positive for antibody against thyroid peroxidase (TPOAb) before treatment and positive for antibody against thyroid globulin (TgAb) during the treatment as compared with those who did not develop thyroid disease ( P ＜ 0.05 ).Conclusion Patients with chronic hepatitis B treated with polyethylene glycol (peg) interferon-α therapy are prone to develop thyroid disease.Women positive for TPOAb and TgAb may be at increased risk for developing thyroid disease.
